Copyright Reports & Markets. All rights reserved.

Global Hepatitis Drugs Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Hepatitis Drugs Market Overview

      • 1.1 Product Overview and Scope of Hepatitis Drugs
      • 1.2 Hepatitis Drugs Segment by Type
        • 1.2.1 Global Hepatitis Drugs Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 VEMLIDY
        • 1.2.3 EPCLUSA
        • 1.2.4 SOVALDI
        • 1.2.5 INCIVEK
        • 1.2.6 OLYSIO
        • 1.2.7 VICTRELIS
        • 1.2.8 VIREAD
        • 1.2.9 HEPSERA
        • 1.2.10 BARACLUDE
        • 1.2.11 TYZEKA
      • 1.3 Hepatitis Drugs Segment by Application
        • 1.3.1 Hepatitis Drugs Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hepatitis A
        • 1.3.3 Hepatitis B
        • 1.3.4 Hepatitis C
        • 1.3.5 Hepatitis D
        • 1.3.6 Hepatitis E
      • 1.4 Global Hepatitis Drugs Market by Region
        • 1.4.1 Global Hepatitis Drugs Market Size Region
        • 1.4.2 North America Status and Prospect (2014-2025)
        • 1.4.3 Europe Status and Prospect (2014-2025)
        • 1.4.4 China Status and Prospect (2014-2025)
        • 1.4.5 Japan Status and Prospect (2014-2025)
      • 1.5 Global Hepatitis Drugs Market Size
        • 1.5.1 Global Hepatitis Drugs Revenue (2014-2025)
        • 1.5.2 Global Hepatitis Drugs Production (2014-2025)

      2 Global Hepatitis Drugs Market Competition by Manufacturers

      • 2.1 Global Hepatitis Drugs Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Hepatitis Drugs Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Hepatitis Drugs Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Hepatitis Drugs Production Sites, Area Served, Product Types
      • 2.5 Hepatitis Drugs Market Competitive Situation and Trends
        • 2.5.1 Hepatitis Drugs Market Concentration Rate
        • 2.5.2 Hepatitis Drugs Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Hepatitis Drugs Production Market Share by Regions

      • 3.1 Global Hepatitis Drugs Production Market Share by Regions
      • 3.2 Global Hepatitis Drugs Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Hepatitis Drugs Production
        • 3.4.1 North America Hepatitis Drugs Production Growth Rate (2014-2019)
        • 3.4.2 North America Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Hepatitis Drugs Production
        • 3.5.1 Europe Hepatitis Drugs Production Growth Rate (2014-2019)
        • 3.5.2 Europe Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Hepatitis Drugs Production (2014-2019)
        • 3.6.1 China Hepatitis Drugs Production Growth Rate (2014-2019)
        • 3.6.2 China Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Hepatitis Drugs Production (2014-2019)
        • 3.7.1 Japan Hepatitis Drugs Production Growth Rate (2014-2019)
        • 3.7.2 Japan Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Hepatitis Drugs Consumption by Regions

      • 4.1 Global Hepatitis Drugs Consumption by Regions
      • 4.2 North America Hepatitis Drugs Consumption (2014-2019)
      • 4.3 Europe Hepatitis Drugs Consumption (2014-2019)
      • 4.4 China Hepatitis Drugs Consumption (2014-2019)
      • 4.5 Japan Hepatitis Drugs Consumption (2014-2019)

      5 Global Hepatitis Drugs Production, Revenue, Price Trend by Type

      • 5.1 Global Hepatitis Drugs Production Market Share by Type (2014-2019)
      • 5.2 Global Hepatitis Drugs Revenue Market Share by Type (2014-2019)
      • 5.3 Global Hepatitis Drugs Price by Type (2014-2019)
      • 5.4 Global Hepatitis Drugs Production Growth by Type (2014-2019)

      6 Global Hepatitis Drugs Market Analysis by Applications

      • 6.1 Global Hepatitis Drugs Consumption Market Share by Application (2014-2019)
      • 6.2 Global Hepatitis Drugs Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Hepatitis Drugs Business

      • 7.1 F. Hoffmann-La Roche
        • 7.1.1 F. Hoffmann-La Roche Hepatitis Drugs Production Sites and Area Served
        • 7.1.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.1.3 F. Hoffmann-La Roche Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Gilead Sciences
        • 7.2.1 Gilead Sciences Hepatitis Drugs Production Sites and Area Served
        • 7.2.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.2.3 Gilead Sciences Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 GlaxoSmithKline
        • 7.3.1 GlaxoSmithKline Hepatitis Drugs Production Sites and Area Served
        • 7.3.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.3.3 GlaxoSmithKline Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Johnson & Johnson
        • 7.4.1 Johnson & Johnson Hepatitis Drugs Production Sites and Area Served
        • 7.4.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.4.3 Johnson & Johnson Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Merck
        • 7.5.1 Merck Hepatitis Drugs Production Sites and Area Served
        • 7.5.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.5.3 Merck Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Novartis
        • 7.6.1 Novartis Hepatitis Drugs Production Sites and Area Served
        • 7.6.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.6.3 Novartis Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Vertex Pharmaceuticals
        • 7.7.1 Vertex Pharmaceuticals Hepatitis Drugs Production Sites and Area Served
        • 7.7.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.7.3 Vertex Pharmaceuticals Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Abbvie
        • 7.8.1 Abbvie Hepatitis Drugs Production Sites and Area Served
        • 7.8.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.8.3 Abbvie Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 Achillion Pharmaceuticals
        • 7.9.1 Achillion Pharmaceuticals Hepatitis Drugs Production Sites and Area Served
        • 7.9.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.9.3 Achillion Pharmaceuticals Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Bristol-Myers Squibb
        • 7.10.1 Bristol-Myers Squibb Hepatitis Drugs Production Sites and Area Served
        • 7.10.2 Hepatitis Drugs Product Introduction, Application and Specification
        • 7.10.3 Bristol-Myers Squibb Hepatitis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served

      8 Hepatitis Drugs Manufacturing Cost Analysis

      • 8.1 Hepatitis Drugs Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Hepatitis Drugs
      • 8.4 Hepatitis Drugs Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Hepatitis Drugs Distributors List
      • 9.3 Hepatitis Drugs Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Hepatitis Drugs Market Forecast

      • 11.1 Global Hepatitis Drugs Production, Revenue Forecast
        • 11.1.1 Global Hepatitis Drugs Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Hepatitis Drugs Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Hepatitis Drugs Price and Trend Forecast (2019-2025)
      • 11.2 Global Hepatitis Drugs Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Hepatitis Drugs Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Hepatitis Drugs Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Hepatitis Drugs Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Hepatitis Drugs Production, Revenue Forecast (2019-2025)
      • 11.3 Global Hepatitis Drugs Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Hepatitis Drugs Consumption Forecast (2019-2025)
        • 11.3.2 Europe Hepatitis Drugs Consumption Forecast (2019-2025)
        • 11.3.3 China Hepatitis Drugs Consumption Forecast (2019-2025)
        • 11.3.4 Japan Hepatitis Drugs Consumption Forecast (2019-2025)
      • 11.4 Global Hepatitis Drugs Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Hepatitis Drugs Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.
        Factors such as growth in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.
        The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2017. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.

        The global Hepatitis Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Hepatitis Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hepatitis Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        F. Hoffmann-La Roche
        Gilead Sciences
        GlaxoSmithKline
        Johnson & Johnson
        Merck
        Novartis
        Vertex Pharmaceuticals
        Abbvie
        Achillion Pharmaceuticals
        Bristol-Myers Squibb

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        VEMLIDY
        EPCLUSA
        SOVALDI
        INCIVEK
        OLYSIO
        VICTRELIS
        VIREAD
        HEPSERA
        BARACLUDE
        TYZEKA

        Segment by Application
        Hepatitis A
        Hepatitis B
        Hepatitis C
        Hepatitis D
        Hepatitis E

        Buy now